Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209117 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01209117: Completed Phase 1 study, sponsored by ViiV Healthcare.
NCT01209117 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01209117, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a single-center, randomized, two part, open-label, crossover study in healthy adult subjects to assess the oral bioavailability of three GSK2248761 Wet Bead Milled (WBM) tablet formulations manufactured by three different processes relative to the GSK2248761 WBM capsule formulation (Part A) and the effect of a moderate-fat meal on the bioavailability of the selected WBM tablet formulation (Part B).
Interventions
- DRUG GSK2248761 WBM Capsule
- DRUG GSK2248761 WBM Tablet Formulation 1
- DRUG GSK2248761 WBM Tablet Formulation 2
- DRUG GSK2248761 WBM Tablet Formulation 3
- DRUG GSK2248761 WBM Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
What the finished NCT01209117 record still lists
NCT01209117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 5 interventions - of which GSK2248761 WBM Capsule is the first listed.
NCT01209117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01209117 about?
NCT01209117 is a clinical study titled "A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435". This is a single-center, randomized, two part, open-label, crossover study in healthy adult subjects to assess the oral bioavailability of three GSK2248761 Wet Bead Milled (WBM) tablet formulations manufactured by three different processes relative to the GSK2248761 WBM capsule formulation (Part A) ...
What is the current status of trial NCT01209117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-09. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01209117?
The interventions under investigation include: GSK2248761 WBM Capsule (DRUG), GSK2248761 WBM Tablet Formulation 1 (DRUG), GSK2248761 WBM Tablet Formulation 2 (DRUG), GSK2248761 WBM Tablet Formulation 3 (DRUG), GSK2248761 WBM Tablet (DRUG).
Who is sponsoring clinical trial NCT01209117?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01209117's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia